Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Vaccines

  Free Subscription


Articles published in J Infect Dis

Retrieve available abstracts of 177 articles:
HTML format
Text format



Single Articles


    September 2017
  1. LEVINE MZ, Holiday C, Liu F, Jefferson S, et al
    Cross-Reactive Antibody Responses to Novel H5Nx Influenza Viruses Following Homologous and Heterologous Prime-Boost Vaccination with a Prepandemic Stockpiled A(H5N1) Vaccine in Humans.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available


  2. JONES EN, Amoah S, Cao W, Sambhara S, et al
    An Adjuvanted A(H5N1) Subvirion Vaccine Elicits Virus-Specific Antibody Response and Improves Protection Against Lethal Influenza Viral Challenge in Mouse Model of Protein Energy Malnutrition.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available


  3. PODDIGHE D
    2-Dose Schedule of AS04-Adjuvanted Human Papillomavirus Types 16/18 Vaccine.
    J Infect Dis. 2017;216:782-783.
    PubMed     Text format    


  4. TAI CS, Wu JF, Chen HL, Ni YH, et al
    The Impact of Hepatitis B Vaccine Failure on Long-term Natural Course of Chronic Hepatitis B Virus Infection in Hepatitis B e Antigen-Seropositive Children.
    J Infect Dis. 2017;216:662-669.
    PubMed     Text format     Abstract available


  5. OLIVER SE, Unger ER, Lewis R, McDaniel D, et al
    Prevalence of Human Papillomavirus Among Females After Vaccine Introduction-National Health and Nutrition Examination Survey, United States, 2003-2014.
    J Infect Dis. 2017;216:594-603.
    PubMed     Text format     Abstract available


    August 2017
  6. NEUZIL KM, Chen WH
    Influenza Vaccines for Older Persons: Progress and Pitfalls.
    J Infect Dis. 2017;216:397-398.
    PubMed     Text format    


  7. ANDREW MK, Shinde V, Ye L, Hatchette T, et al
    The Importance of Frailty in the Assessment of Influenza Vaccine Effectiveness Against Influenza-Related Hospitalization in Elderly People.
    J Infect Dis. 2017;216:405-414.
    PubMed     Text format     Abstract available


  8. VAN BEEK J, Veenhoven RH, Bruin JP, van Boxtel RAJ, et al
    Influenza-like Illness Incidence Is Not Reduced by Influenza Vaccination in a Cohort of Older Adults, Despite Effectively Reducing Laboratory-Confirmed Influenza Virus Infections.
    J Infect Dis. 2017;216:415-424.
    PubMed     Text format     Abstract available


  9. MCELHANEY JE, McNeil SA
    Test-Negative Design: The Importance of Laboratory-Confirmed Illness in Estimating the Effectiveness of Influenza Vaccine in Older Adults.
    J Infect Dis. 2017;216:399-401.
    PubMed     Text format    


  10. LIBRATY DH
    Effect of an Early Dose of Measles Vaccine on Morbidity Between 18 Weeks and 9 Months of Age: A Randomized, Controlled Trial in Guinea-Bissau.
    J Infect Dis. 2017;216:502-503.
    PubMed     Text format    


  11. LIU J, Qiu S, Lu J, Yan B, et al
    Robust Antibody and Cytokine Response to Hepatitis B Vaccine Among Not-in-Treatment Patients With Chronic Hepatitis C: An Open-Label Control Study in China.
    J Infect Dis. 2017;216:327-335.
    PubMed     Text format     Abstract available


  12. BAUSSANO I, Lazzarato F, Ronco G, Lehtinen M, et al
    Different Challenges in Eliminating HPV16 Compared to Other Types: A Modeling Study.
    J Infect Dis. 2017;216:336-344.
    PubMed     Text format     Abstract available


  13. MOHAN VR, Karthikeyan R, Babji S, McGrath M, et al
    Rotavirus Infection and Disease in a Multisite Birth Cohort: Results From the MAL-ED Study.
    J Infect Dis. 2017;216:305-316.
    PubMed     Text format     Abstract available


    July 2017
  14. VERSCHOOR CP, Lelic A, Parsons R, Evelegh C, et al
    Serum C-Reactive Protein and Congestive Heart Failure as Significant Predictors of Herpes Zoster Vaccine Response in Elderly Nursing Home Residents.
    J Infect Dis. 2017;216:191-197.
    PubMed     Text format     Abstract available


  15. OPERARIO DJ, Platts-Mills JA, Nadan S, Page N, et al
    Etiology of Severe Acute Watery Diarrhea in Children in the Global Rotavirus Surveillance Network Using Quantitative Polymerase Chain Reaction.
    J Infect Dis. 2017;216:220-227.
    PubMed     Text format     Abstract available


  16. HOLMES M, Abimbola T, Lusiana M, Pallas S, et al
    Resource Needs for the Trivalent Oral Polio to Bivalent Oral Polio Vaccine Switch in Indonesia.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available


  17. ZIPURSKY S, Patel M, Farrell M, Gonzalez AR, et al
    Lessons Learned From Managing the Planning and Implementation of Inactivated Polio Vaccine Introduction in Support of the Polio Endgame.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available


  18. NNADI C, Etsano A, Uba B, Ohuabunwo C, et al
    Approaches to Vaccination Among Populations in Areas of Conflict.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available


  19. WALLACE AS, Bohara R, Stewart S, Subedi G, et al
    Impact of an Intervention to Use a Measles, Rubella, and Polio Mass Vaccination Campaign to Strengthen Routine Immunization Services in Nepal.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available


  20. FAHMY K, Hampton LM, Langar H, Patel M, et al
    Introduction of Inactivated Polio Vaccine, Withdrawal of Type 2 Oral Polio Vaccine, and Routine Immunization Strengthening in the Eastern Mediterranean Region.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available


  21. THOMPSON KM, Duintjer Tebbens RJ
    Lessons From Globally Coordinated Cessation of Serotype 2 Oral Poliovirus Vaccine for the Remaining Serotypes.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available


  22. BURNETT E, Wannemuehler K, Ngoie Mwamba G, Yolande M, et al
    Individually Linked Household and Health Facility Vaccination Survey in 12 At-risk Districts in Kinshasa Province, Democratic Republic of Congo: Methods and Metadata.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available


  23. THOMPSON KM, Duintjer Tebbens RJ
    Lessons From the Polio Endgame: Overcoming the Failure to Vaccinate and the Role of Subpopulations in Maintaining Transmission.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available


  24. HAMPTON LM, du Chatellier GM, Fournier-Caruana J, Ottosen A, et al
    Considerations for the Full Global Withdrawal of Oral Polio Vaccine After Eradication of Polio.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available


  25. DIOP OM, Kew OM, de Gourville EM, Pallansch MA, et al
    The Global Polio Laboratory Network as a Platform for the Viral Vaccine-Preventable and Emerging Diseases Laboratory Networks.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available


  26. MULDERS MN, Serhan F, Goodson JL, Icenogle J, et al
    Expansion of Surveillance for Vaccine-preventable Diseases: Building on the Global Polio Laboratory Network and the Global Measles and Rubella Laboratory Network Platforms.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available


  27. MENNING L, Garg G, Pokharel D, Thrush E, et al
    Communications, Immunization, and Polio Vaccines: Lessons From a Global Perspective on Generating Political Will, Informing Decision-Making and Planning, and Engaging Local Support.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available


  28. DOLAN SB, Patel M, Hampton LM, Burnett E, et al
    Administering Multiple Injectable Vaccines During a Single Visit-Summary of Findings From the Accelerated Introduction of Inactivated Polio Vaccine Globally.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available


  29. OSADEBE LU, MacNeil A, Elmousaad H, Davis L, et al
    Assessing Inactivated Polio Vaccine Introduction and Utilization in Kano State, Nigeria, April-November 2015.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available


  30. OKAYASU H, Sein C, Chang Blanc D, Gonzalez AR, et al
    Intradermal Administration of Fractional Doses of Inactivated Poliovirus Vaccine: A Dose-Sparing Option for Polio Immunization.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available


  31. RAMIREZ GONZALEZ A, Farrell M, Menning L, Garon J, et al
    Implementing the Synchronized Global Switch from Trivalent to Bivalent Oral Polio Vaccines-Lessons Learned From the Global Perspective.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available


  32. TEVI-BENISSAN C, Okeibunor J, du Chatellier GM, Assefa A, et al
    Introduction of Inactivated Poliovirus Vaccine and Trivalent Oral Polio Vaccine/Bivalent Oral Polio Vaccine Switch in the African Region.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available


  33. BAHL S, Hasman A, Eltayeb AO, James Noble D, et al
    The Switch From Trivalent to Bivalent Oral Poliovirus Vaccine in the South-East Asia Region.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available


  34. BA-NGUZ A, Adjagba A, Wisnu Hendrarto T, Sewankambo NK, et al
    The Role of National Immunization Technical Advisory Groups (NITAGs) in the Introduction of Inactivated Polio Vaccine: Experience of the Indonesia and Uganda NITAGs.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available


  35. WASSILAK SGF, Williams CL, Murrill CS, Dahl BA, et al
    Using Acute Flaccid Paralysis Surveillance as a Platform for Vaccine-Preventable Disease Surveillance.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available


  36. BILLAH MM, Zaman K, Estivariz CF, Snider CJ, et al
    Cold-Chain Adaptability During Introduction of Inactivated Polio Vaccine in Bangladesh, 2015.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available


  37. SHENDALE S, Farrell M, Hampton LM, Harris JB, et al
    Financial Support to Eligible Countries for the Switch From Trivalent to Bivalent Oral Polio Vaccine-Lessons Learned.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available


  38. GURUNG S, Harris JB, Eltayeb AO, Hampton LM, et al
    Experience With Inactivated Polio Vaccine Introduction and the "Switch" From Trivalent to Bivalent Oral Polio Vaccine in the World Health Organization's Western Pacific Region.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available


  39. BLANKENHORN AL, Cernuschi T, Zaffran MJ
    Exceptional Financial Support for Introduction of Inactivated Polio Vaccine in Middle-Income Countries.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available


  40. WANYOIKE S, Ramirez Gonzalez A, Dolan SB, Garon J, et al
    Disposing of Excess Vaccines After the Withdrawal of Oral Polio Vaccine.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available


  41. RUBIN J, Ottosen A, Ghazieh A, Fournier-Caruana J, et al
    Managing the Planned Cessation of a Global Supply Market: Lessons Learned From the Global Cessation of the Trivalent Oral Poliovirus Vaccine Market.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available


  42. PREZA I, Subaiya S, Harris JB, Ehlman DC, et al
    Acceptance of the Administration of Multiple Injectable Vaccines in a Single Immunization Visit in Albania.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available


  43. DECINA D, Fournier-Caruana J, Takane M, Ostad Ali Dehaghi R, et al
    Regulatory Aspects of Sabin Type 2 Withdrawal From Trivalent Oral Poliovirus Vaccine: Process and Lessons Learned.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available


  44. LEWIS I, Ottosen A, Rubin J, Blanc DC, et al
    A Supply and Demand Management Perspective on the Accelerated Global Introductions of Inactivated Poliovirus Vaccine in a Constrained Supply Market.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available


  45. SCOTNEY S, Snidal S, Saidu Y, Ojumu A, et al
    Succeeding in New Vaccine Introduction: Lessons Learned From the Introduction of Inactivated Poliovirus Vaccine in Cameroon, Kenya, and Nigeria.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available


  46. ONGWAE KM, Bawa SB, Shuaib F, Braka F, et al
    Use of Dedicated Mobile Teams and Polio Volunteer Community Mobilizers to Increase Access to Zero-Dose Oral Poliovirus Vaccine and Routine Childhood Immunizations in Settlements at High Risk for Polio Transmission in Northern Nigeria.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available


  47. ESTIVARIZ CF, Snider CJ, Anand A, Hampton LM, et al
    Lessons Learned From the Introduction of Inactivated Poliovirus Vaccine in Bangladesh.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available


  48. FARRELL M, Hampton LM, Shendale S, Menning L, et al
    Monitoring and Validation of the Global Replacement of tOPV with bOPV, April-May 2016.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available


  49. GUIRGUIS S, Obregon R, Coleman M, Hickler B, et al
    Placing Human Behavior at the Center of the Fight to Eradicate Polio: Lessons Learned and Their Application to Other Life-Saving Interventions.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available


  50. PATEL M, Cochi S
    Addressing the Challenges and Opportunities of the Polio Endgame: Lessons for the Future.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available


  51. ZIPURSKY S, Vandelaer J, Brooks A, Dietz V, et al
    Polio Endgame: Lessons Learned From the Immunization Systems Management Group.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available


  52. PEDREIRA C, Thrush E, Jauregui B
    Systematization of the Introduction of IPV and Switch from tOPV to bOPV in the Americas.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available


    June 2017
  53. LAVERDE D, Probst I, Romero-Saavedra F, Kropec A, et al
    Targeting Type IV Secretion System Proteins to Combat Multidrug-Resistant Gram-positive Pathogens.
    J Infect Dis. 2017;215:1836-1845.
    PubMed     Text format     Abstract available


  54. MAERTENS K, Tran TMP, Hens N, Van Damme P, et al
    Effect of Prepregnancy Pertussis Vaccination in Young Infants.
    J Infect Dis. 2017;215:1855-1861.
    PubMed     Text format     Abstract available


  55. MONTO AS, Malosh RE, Petrie JG, Martin ET, et al
    The Doctrine of Original Antigenic Sin: Separating Good From Evil.
    J Infect Dis. 2017;215:1782-1788.
    PubMed     Text format     Abstract available


  56. CHUNG JR, Flannery B, Zimmerman RK, Nowalk MP, et al
    Prior season vaccination and risk of influenza during the 2014-2015 season in the U.S.
    J Infect Dis. 2017 Jun 13. doi: 10.1093.
    PubMed     Text format    


  57. HUANG LM, Puthanakit T, Cheng-Hsun C, Ren-Bin T, et al
    Sustained Immunogenicity of 2-dose Human Papillomavirus 16/18 AS04-adjuvanted Vaccine Schedules in Girls Aged 9-14 Years: A Randomized Trial.
    J Infect Dis. 2017 Jun 7. doi: 10.1093.
    PubMed     Text format     Abstract available


  58. QENDRI V, Bogaards JA, Berkhof J
    Health and economic impact of a tender-based gender-neutral HPV16/18 vaccination program in the Netherlands.
    J Infect Dis. 2017 Jun 6. doi: 10.1093.
    PubMed     Text format     Abstract available


    May 2017
  59. HALPERIN SA, Arribas JR, Rupp R, Andrews CP, et al
    Six-Month Safety Data of Recombinant Vesicular Stomatitis Virus-Zaire Ebola Virus Envelope Glycoprotein Vaccine in a Phase 3 Double-Blind, Placebo-Controlled Randomized Study in Healthy Adults.
    J Infect Dis. 2017 May 26. doi: 10.1093.
    PubMed     Text format     Abstract available


  60. FLECKENSTEIN JM
    Providing Structure to Enterotoxigenic Escherichia coli Vaccine Development.
    J Infect Dis. 2017 May 24. doi: 10.1093.
    PubMed     Text format    


  61. LOCHT C, Papin JF, Lecher S, Debrie AS, et al
    Live attenuated pertussis vaccine BPZE1 protects baboons against B. pertussis disease and infection.
    J Infect Dis. 2017 May 23. doi: 10.1093.
    PubMed     Text format     Abstract available


  62. YAO Y, Lai R, Afkhami S, Haddadi S, et al
    A novel virus-vectored respiratory mucosal vaccine enhances anti-tuberculosis immunity in a humanized model system.
    J Infect Dis. 2017 May 20. doi: 10.1093.
    PubMed     Text format     Abstract available


    April 2017
  63. SCHNELL MJ
    Editorial to: 6-Month Safety Data of Ebola Zaire Vaccine (rVSVDeltaG-ZEBOV-GP) in a Phase III Double Blind, Placebo Controlled Randomized Study in Healthy Adults.
    J Infect Dis. 2017 Apr 18. doi: 10.1093.
    PubMed     Text format    


  64. S NELSON EA, Steele AD
    Global Impact of Rotavirus Vaccination on Childhood Hospitalizations and Mortality from Diarrhea.
    J Infect Dis. 2017 Apr 18. doi: 10.1093.
    PubMed     Text format    


  65. BURNETT E, Jonesteller CL, Tate JE, Yen C, et al
    Global Impact of Rotavirus Vaccination on Childhood Hospitalizations and Mortality from Diarrhea.
    J Infect Dis. 2017 Apr 18. doi: 10.1093.
    PubMed     Text format     Abstract available


  66. RERKS-NGARM S, Pitisuttithum P, Excler JL, Nitayaphan S, et al
    Randomized, Double-Blind Evaluation of Late Boost Strategies for HIV-Uninfected Vaccine Recipients in the RV144 HIV Vaccine Efficacy Trial.
    J Infect Dis. 2017;215:1255-1263.
    PubMed     Text format     Abstract available


  67. LI D, Wang X, von Schaewen M, Tao W, et al
    Immunization with a subunit hepatitis C virus vaccine elicits pan-genotypic neutralizing antibodies and intra-hepatic T-cell responses in non-human primates.
    J Infect Dis. 2017 Apr 8. doi: 10.1093.
    PubMed     Text format     Abstract available


    March 2017
  68. MOHN KG, Zhou F, Brokstad KA, Sridhar S, et al
    Live attenuated influenza vaccination boosts durable cross-reactive and protection-associated T-cells in children.
    J Infect Dis. 2017 Mar 27. doi: 10.1093.
    PubMed     Text format     Abstract available


  69. BUCKWALTER CM, Currie EG, Tsang RS, Gray-Owen SD, et al
    Licensed meningococcal serogroup B vaccine-induced immunity against invasive disease does not reflect protection against nasal colonization in a humanized mouse model.
    J Infect Dis. 2017 Mar 27. doi: 10.1093.
    PubMed     Text format     Abstract available


  70. FLANAGAN KL
    Measles Vaccination Is Effective at Under Nine Months of Age, and Provides Nonspecific Immunological Benefits.
    J Infect Dis. 2017 Mar 23. doi: 10.1093.
    PubMed     Text format     Abstract available


  71. WOUDENBERG T, van der Maas NA, Knol MJ, de Melker H, et al
    Effectiveness of Early Measles, Mumps, and Rubella Vaccination Among 6-14-Month-Old Infants During an Epidemic in the Netherlands: An Observational Cohort Study.
    J Infect Dis. 2017 Mar 23. doi: 10.1093.
    PubMed     Text format     Abstract available


  72. PETRIE JG, Monto AS
    Untangling the Effects of Prior Vaccination on Subsequent Influenza Vaccine Effectiveness.
    J Infect Dis. 2017;215:841-843.
    PubMed     Text format    


  73. MARTINEZ-BAZ I, Casado I, Navascues A, Diaz-Gonzalez J, et al
    Effect of Repeated Vaccination With the Same Vaccine Component Against 2009 Pandemic Influenza A(H1N1) Virus.
    J Infect Dis. 2017;215:847-855.
    PubMed     Text format     Abstract available


  74. UPRETY P, Lindsey JC, Levin MJ, Rainwater-Lovett K, et al
    Inflammation and Immune Activation in Antiretroviral-Treated Human Immunodeficiency Virus Type 1-Infected African Infants and Rotavirus Vaccine Responses.
    J Infect Dis. 2017;215:928-932.
    PubMed     Text format     Abstract available


  75. LINDESMITH LC, Mallory ML, Jones TA, Richardson C, et al
    Impact of Pre-exposure History and Host Genetics on Antibody Avidity Following Norovirus Vaccination.
    J Infect Dis. 2017;215:984-991.
    PubMed     Text format     Abstract available


  76. COHEN JI
    Vaccination to Reduce Reactivation of Herpes Simplex Virus Type 2.
    J Infect Dis. 2017;215:844-846.
    PubMed     Text format    


  77. SINGH P, Verma D, Backstedt BT, Kaur S, et al
    Borrelia burgdorferi BBI39 Paralogs, Targets of Protective Immunity, Reduce Pathogen Persistence Either in Hosts or in the Vector.
    J Infect Dis. 2017;215:1000-1009.
    PubMed     Text format     Abstract available


  78. SHAY DK, Chillarige Y, Kelman J, Forshee RA, et al
    Comparative Effectiveness of High-Dose Versus Standard-Dose Influenza Vaccines Among US Medicare Beneficiaries in Preventing Postinfluenza Deaths During 2012-2013 and 2013-2014.
    J Infect Dis. 2017 Mar 2. doi: 10.1093.
    PubMed     Text format     Abstract available


  79. MONTO AS
    Moving Toward Improved Influenza Vaccines.
    J Infect Dis. 2017 Mar 2. doi: 10.1093.
    PubMed     Text format    


    February 2017
  80. KARAUZUM H, Haudenschild CC, Moore IN, Mahmoudieh M, et al
    Vaccination induces CD4 T cell-mediated mortality during Staphylococcus aureus bacteremia.
    J Infect Dis. 2017 Feb 21. doi: 10.1093.
    PubMed     Text format     Abstract available


  81. JANES HE, Cohen KW, Frahm N, De Rosa SC, et al
    Higher T cell responses induced by DNA/rAd5 HIV-1 preventive vaccine are associated with lower HIV-1 infection risk in an efficacy trial.
    J Infect Dis. 2017 Feb 12. doi: 10.1093.
    PubMed     Text format    


  82. SKOWRONSKI DM, Chambers C, De Serres G, Sabaiduc S, et al
    Serial vaccination and the antigenic distance hypothesis: effects on influenza vaccine effectiveness during A(H3N2) epidemics in Canada, 2010-11 to 2014-15.
    J Infect Dis. 2017 Feb 9. doi: 10.1093.
    PubMed     Text format    



  83. Flu vaccine - too much of a good thing?
    J Infect Dis. 2017 Feb 7. doi: 10.1093.
    PubMed     Text format    


  84. PETRIE JG, Monto AS
    Untangling the Effects of Prior Vaccination on Subsequent Influenza Vaccine Effectiveness.
    J Infect Dis. 2017 Feb 7. doi: 10.1093.
    PubMed     Text format    


  85. MARTINEZ-BAZ I, Casado I, Navascues A, Diaz-Gonzalez J, et al
    Effect of Repeated Vaccination With the Same Vaccine Component Against Influenza A(H1N1)pdm09.
    J Infect Dis. 2017 Feb 7. doi: 10.1093.
    PubMed     Text format    


  86. UPRETY P, Lindsey JC, Levin MJ, Rainwater-Lovett K, et al
    Inflammation and Immune Activation in Antiretroviral-Treated HIV-1-Infected African Infants and Rotavirus Vaccine Responses.
    J Infect Dis. 2017 Feb 7. doi: 10.1093.
    PubMed     Text format    


  87. LINDESMITH LC, Mallory ML, Jones TA, Richardson C, et al
    Impact of Pre-Exposure History and Host Genetics on Antibody Avidity Following Norovirus Vaccination.
    J Infect Dis. 2017 Feb 1. doi: 10.1093.
    PubMed     Text format    


    January 2017
  88. BERNSTEIN DI, Wald A, Warren T, Fife K, et al
    Therapeutic Vaccine for Genital Herpes Simplex Virus-2 Infection: Findings from a Randomized Trial.
    J Infect Dis. 2017 Jan 30. doi: 10.1093.
    PubMed     Text format     Abstract available


  89. CLARK S, Lanni F, Marinova D, Rayner E, et al
    Revaccination of Guinea Pigs With the Live Attenuated Mycobacterium tuberculosis Vaccine MTBVAC Improves BCG's Protection Against Tuberculosis.
    J Infect Dis. 2017 Jan 25. doi: 10.1093.
    PubMed     Text format     Abstract available


  90. KAZI AM, Cortese MM, Yu Y, Lopman B, et al
    Secretor and salivary ABO blood group antigen status predict rotavirus vaccine-take in infants.
    J Infect Dis. 2017 Jan 18. doi: 10.1093.
    PubMed     Text format     Abstract available


  91. FEROLDI E, Boaz M, Yoksan S, Chokephaibulkit K, et al
    Persistence of Wild-Type Japanese Encephalitis Virus Strains Cross-Neutralization 5 Years After JE-CV Immunization.
    J Infect Dis. 2017;215:221-227.
    PubMed     Text format     Abstract available


  92. COHEN JI
    Vaccination to Reduce Reactivation of Herpes Simplex Virus 2.
    J Infect Dis. 2017 Jan 11. pii: jix006. doi: 10.1093.
    PubMed     Text format    


  93. DO VA, Biering-Sorensen S, Fisker AB, Bale C, et al
    Effect of an Early Dose of Measles Vaccine on Morbidity Between 18 Weeks and 9 Months of Age: A Randomized, Controlled Trial in Guinea-Bissau.
    J Infect Dis. 2017 Jan 10. pii: jiw512. doi: 10.1093.
    PubMed     Text format     Abstract available


  94. RESIK S, Tejeda A, Diaz M, Okayasu H, et al
    Boosting Immune Responses Following Fractional-Dose Inactivated Poliovirus Vaccine: A Randomized, Controlled Trial.
    J Infect Dis. 2017 Jan 9. pii: jiw492. doi: 10.1093.
    PubMed     Text format     Abstract available


  95. NYOMBAYIRE J, Anzala O, Gazzard B, Karita E, et al
    First-in-Human Evaluation of the Safety and Immunogenicity of an Intranasally Administered Replication-Competent Sendai Virus-Vectored HIV Type 1 Gag Vaccine: Induction of Potent T-Cell or Antibody Responses in Prime-Boost Regimens.
    J Infect Dis. 2017;215:95-104.
    PubMed     Text format     Abstract available


  96. WEI M, Meng F, Wang S, Li J, et al
    2-Year Efficacy, Immunogenicity, and Safety of Vigoo Enterovirus 71 Vaccine in Healthy Chinese Children: A Randomized Open-Label Study.
    J Infect Dis. 2017;215:56-63.
    PubMed     Text format     Abstract available


  97. PIERCE KK, Whitehead SS, Kirkpatrick BD, Grier PL, et al
    A Live Attenuated Chimeric West Nile Virus Vaccine, rWN/DEN4Delta30, Is Well Tolerated and Immunogenic in Flavivirus-Naive Older Adult Volunteers.
    J Infect Dis. 2017;215:52-55.
    PubMed     Text format     Abstract available


  98. HEIKKINEN T, Ojala E, Waris M
    Clinical and Socioeconomic Burden of Respiratory Syncytial Virus Infection in Children.
    J Infect Dis. 2017;215:17-23.
    PubMed     Text format     Abstract available


    December 2016
  99. HADLER JL
    Christmas-New Year influenza lull: not too late for vaccination.
    J Infect Dis. 2016 Dec 28. pii: jiw643. doi: 10.1093.
    PubMed     Text format    


  100. MANOR Y, Lewis M, Ram D, Daudi N, et al
    Evidence for Hepatitis A Virus Endemic Circulation in Israel Despite Universal Toddler Vaccination Since 1999 and Low Clinical Incidence in All Age Groups.
    J Infect Dis. 2016 Dec 24. doi: 10.1093.
    PubMed     Text format    


  101. MANOR Y, Lewis M, Ram D, Daudi N, et al
    Evidence for Hepatitis A virus endemic circulation in Israel despite universal toddlers' vaccination since 1999 and low clinical incidence in all age groups.
    J Infect Dis. 2016 Dec 23. pii: jiw611. doi: 10.1093.
    PubMed     Text format     Abstract available


  102. CHENG A, Chang SY, Sun HY, Tsai MS, et al
    Long-term durability of responses to 2 or 3 doses of hepatitis A vaccination in HIV-positive adults on antiretroviral therapy.
    J Infect Dis. 2016 Dec 23. pii: jiw605. doi: 10.1093.
    PubMed     Text format     Abstract available


  103. DONKEN R, Schurink-van 't Klooster TM, Schepp RM, van der Klis FR, et al
    Immune responses after two- versus three-doses of HPV vaccination up to 4(1/2) years post vaccination: an observational study among Dutch routinely vaccinated girls (HPV2D).
    J Infect Dis. 2016 Dec 23. pii: jiw588. doi: 10.1093.
    PubMed     Text format     Abstract available


  104. MOSLEY YC, Radder JE, Berndt A, HogenEsch H, et al
    Genome-Wide Association Mapping of the Antibody Response to Diphtheria-Tetanus-acellular Pertussis Vaccine in Mice.
    J Infect Dis. 2016 Dec 23. pii: jiw587. doi: 10.1093.
    PubMed     Text format     Abstract available


  105. HEARD I, Tondeur L, Arowas L, Demazoin M, et al
    Effectiveness of HPV vaccination on prevalence of vaccine genotypes in young sexually active women in France.
    J Infect Dis. 2016 Dec 23. pii: jiw639. doi: 10.1093.
    PubMed     Text format     Abstract available


  106. WANG X, Fan X, Bi S, Li N, et al
    Toll-like Receptor 2-and 4-Mediated Reciprocal Th17 and Antibody Responses to Group A Streptococcus Infection.
    J Infect Dis. 2016 Dec 23. pii: jiw598. doi: 10.1093.
    PubMed     Text format     Abstract available


  107. JEGASKANDA S, Co MD, Cruz J, Subbarao K, et al
    Human seasonal influenza A viruses induce H7N9-cross-reactive antibody-dependent cellular cytotoxicity (ADCC) antibodies that are directed towards the nucleoprotein.
    J Infect Dis. 2016 Dec 23. pii: jiw629. doi: 10.1093.
    PubMed     Text format     Abstract available


  108. TRIEU MC, Zhou F, Lartey S, Jul-Larsen A, et al
    Long-term maintenance of the influenza-specific cross-reactive memory CD4+ T-cell responses following repeated annual influenza vaccination.
    J Infect Dis. 2016 Dec 22. pii: jiw619. doi: 10.1093.
    PubMed     Text format     Abstract available


  109. JOHN J, Giri S, Karthikeyan AS, Lata D, et al
    The duration of intestinal immunity after an inactivated poliovirus vaccine booster dose in children immunized with oral vaccine: a randomised controlled trial.
    J Infect Dis. 2016 Dec 21. pii: jiw595. doi: 10.1093.
    PubMed     Text format     Abstract available


  110. PETRIE JG, Parkhouse K, Ohmit SE, Malosh RE, et al
    Antibodies Against the Current Influenza A(H1N1) Vaccine Strain Do Not Protect Some Individuals From Infection With Contemporary Circulating Influenza A(H1N1) Virus Strains.
    J Infect Dis. 2016;214:1947-1951.
    PubMed     Text format     Abstract available


  111. RAMSAUER K, Tangy F
    Chikungunya Virus Vaccines: Viral Vector-Based Approaches.
    J Infect Dis. 2016;214.
    PubMed     Text format     Abstract available


  112. DEZURE AD, Berkowitz NM, Graham BS, Ledgerwood JE, et al
    Whole-Inactivated and Virus-Like Particle Vaccine Strategies for Chikungunya Virus.
    J Infect Dis. 2016;214.
    PubMed     Text format     Abstract available


  113. ERASMUS JH, Rossi SL, Weaver SC
    Development of Vaccines for Chikungunya Fever.
    J Infect Dis. 2016;214.
    PubMed     Text format     Abstract available


  114. HENEIN S, Swanstrom J, Byers AM, Moser JM, et al
    Dissecting antibodies induced by a chimeric yellow fever-dengue, live-attenuated, tetravalent dengue vaccine (CYD-TDV) in naive and dengue exposed individuals.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  115. FEDSON DS
    Statins, Influenza Vaccination and Influenza.
    J Infect Dis. 2016.
    PubMed     Text format    


  116. COLLETT MS, Hincks JR, Benschop K, Duizer E, et al
    Antiviral activity of pocapavir in a randomized, blinded, placebo-controlled human oral poliovirus vaccine challenge model.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  117. FEDSON DS
    Statins, Influenza Vaccination and Influenza.
    J Infect Dis. 2016 Dec 7. doi: 10.1093.
    PubMed     Text format    


    November 2016
  118. BERENSON AB, Laz TH, Rahman M
    Reduction in vaccine-type human papillomavirus prevalence among adult females in the United States, 2009-2012.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  119. ABEID KA, Jani B, Cortese MM, Kamugisha C, et al
    Monovalent Rotavirus Vaccine Effectiveness and Impact on Rotavirus Hospitalizations in Zanzibar, Tanzania: Data from the First 3 Years Post-Introduction.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  120. MACHALEK DA, Chow EP, Garland SM, Wigan R, et al
    Human papillomavirus prevalence in unvaccinated heterosexual males following a national female vaccination program.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


    October 2016
  121. WU Y, Chakravarty S, Li M, Wai TT, et al
    Development of a live attenuated bivalent oral vaccine against Shigella sonnei shigellosis and typhoid fever.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  122. HARRIS VC, Armah G, Fuentes S, Korpela KE, et al
    The infant gut microbiome correlates significantly with rotavirus vaccine response in rural Ghana.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  123. ITURRIZA-GOMARA M, Cunliffe NA
    Could the gut microbiome be key to understanding and improving rotavirus vaccine performance in high disease burden settings?
    J Infect Dis. 2016.
    PubMed     Text format    


  124. SCHLECHT NF, Diaz A, Shankar V, Szporn AH, et al
    RISK OF DELAYED HPV VACCINATION IN INNER-CITY ADOLESCENT WOMEN.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  125. MORI I
    Vaccination Effectively Prevents Central Nervous System Invasion by Influenza A(H5N1) Virus Through the Olfactory Pathway: A Proposed Mechanism of Neuroprotection.
    J Infect Dis. 2016.
    PubMed     Text format    


  126. LELIC A, Verschoor CP, Lau VW, Parsons R, et al
    Immunogenicity of Varicella Zoster Vaccine and Immunologic Predictors of Response in a Cohort of Elderly Nursing Home Residents.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  127. JEYANATHAN M, Damjanovic D, Yao Y, Bramson J, et al
    Induction of an immune protective T cell repertoire with diverse genetic coverage by a novel viral-vectored tuberculosis vaccine in man.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  128. XIONG X, Jiao J, Gregory AE, Wang P, et al
    Identification of Coxiella burnetii CD8+ epitopes and delivery by attenuated Listeria monocytogenes as a vaccine vector in a C57BL/6 mouse model.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available



  129. Live attenuated influenza vaccine in children induces B-cell responses in tonsils.
    J Infect Dis. 2016.
    PubMed     Text format    


    September 2016
  130. ENGLUND JA, Chu HY
    Vaccines Against Respiratory Syncytial Virus: The Time Has Come.
    J Infect Dis. 2016.
    PubMed     Text format    


  131. LANGLEY JM, Aggarwal N, Toma A, Halperin SA, et al
    A randomized, controlled, observer-blind Phase I study of the safety and immunogenicity of a Respiratory Syncytial Virus vaccine with or without alum adjuvant.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  132. HALSTEAD SB
    Dengue Vaccine Efficacy: Not a Zero Sum Game.
    J Infect Dis. 2016.
    PubMed     Text format    


  133. LIAO G, Li R, Li C, Sun M, et al
    Phase III Trial of a Sabin Strain-based Inactivated Poliovirus Vaccine.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  134. GOO L, Dowd KA, Lin TY, Mascola JR, et al
    A virus-like particle vaccine elicits broad neutralizing antibody responses in humans to all Chikungunya virus genotypes.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  135. MADAN A, Segall N, Ferguson M, Frenette L, et al
    Immunogenicity and safety of an AS03-adjuvanted H7N9 pandemic influenza vaccine in a randomized trial in healthy adults.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  136. MAYORGA O, Buhler S, Jaeger VK, Bally S, et al
    Single dose hepatitis A immunisation: 7.5 year observational pilot study in Nicaraguan children to assess protective effectiveness and humoral immune memory response.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


    August 2016
  137. SINGH DK, Dwivedi VP, Ranganathan A, Bishai WR, et al
    Blockade of the Kv1.3 K+ channel enhances BCG vaccine efficacy by expanding central memory T lymphocytes.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  138. REBER AJ, Kim JH, Coleman LA, Spencer SM, et al
    Seasonal Influenza Vaccination of Children Induces Humoral and Cell-Mediated Immunity Beyond the Current Season: Cross-reactivity with Past and Future Strains.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  139. EDWARDS KM, Keitel WA
    Challenges Remain for Influenza Vaccination of Children.
    J Infect Dis. 2016.
    PubMed     Text format    


  140. KIM JH, Mishina M, Chung JR, Cole KS, et al
    Cell-mediated immunity against antigenically drifted influenza A(H3N2) viruses in children during a vaccine mismatch season.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  141. LEWNARD JA, Huppert A, Givon-Lavi N, Pettigrew MM, et al
    Density, serotype diversity, and fitness of Streptococcus pneumoniae in upper respiratory co-colonization with nontypeable Haemophilus influenzae.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  142. SIEGERS JY, van den Brand JM, Leijten LM, van de Bildt MM, et al
    Vaccination Is More Effective Than Prophylactic Oseltamivir in Preventing CNS Invasion by H5N1 Virus via the Olfactory Nerve.
    J Infect Dis. 2016;214:516-24.
    PubMed     Text format     Abstract available


  143. ADLER SP, Manganello AM, Lee R, McVoy MA, et al
    A Phase 1 Study of Four Live, Recombinant Human Cytomegalovirus Towne/Toledo Chimera Vaccines in CMV Seronegative Men.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  144. PINTO LA, Kemp TJ, Torres BN, Isaacs K, et al
    THE QUADRIVALENT HPV VACCINE INDUCES HPV-SPECIFIC ANTIBODIES AT THE ORAL CAVITY: RESULTS FROM THE MID-ADULT MALE VACCINE TRIAL-THE MAM TRIAL.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  145. WILDER-SMITH A, Vannice KS, Hombach J, Farrar J, et al
    Population perspectives and WHO recommendations for CYD-TDV dengue vaccine.
    J Infect Dis. 2016.
    PubMed     Text format    


  146. HALSTEAD S
    Critique of WHO Approval of a Dengue Vaccine.
    J Infect Dis. 2016.
    PubMed     Text format    


  147. WU S, Kroeker A, Wong G, He S, et al
    An Adenovirus Vaccine Expressing Ebola Virus Variant Makona Glycoprotein Is Efficacious in Guinea Pigs and Nonhuman Primates.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available



  148. A Randomized, Controlled Trial of the Impact of Alternative Dosing Schedules on the Immune Response to Human Rotavirus Vaccine in Rural Ghanaian Infants.
    J Infect Dis. 2016.
    PubMed     Text format    


    July 2016
  149. MCLEAN HQ, Chow BD, VanWormer JJ, King JP, et al
    The Effect of Statin Use on Influenza Vaccine Effectiveness.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  150. SHAFER WM
    Does the cervicovaginal microbiome facilitate transmission of Neisseria gonorrhoeae from women to men? Implications for understanding transmission of gonorrhea and advancing vaccine development.
    J Infect Dis. 2016.
    PubMed     Text format    


  151. JOHNSON RF, Kurup D, Hagen KR, Fisher C, et al
    An Inactivated Rabies Virus-Based Ebola Vaccine, FILORAB1, Adjuvanted With Glucopyranosyl Lipid A in Stable Emulsion Confers Complete Protection in Nonhuman Primate Challenge Models.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  152. HOFT DF, Lottenbach K, Goll JB, Hill H, et al
    Priming Vaccination with H5 Hemagglutinin Antigen Significantly Increases the Duration of T cell Responses Induced by a Heterologous H5 Booster Vaccination.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  153. OLIVERA-BOTELLO G, Coudeville L, Fanouillere K, Guy B, et al
    Tetravalent dengue vaccine reduces symptomatic and asymptomatic dengue infections in healthy children and adolescents aged 2-16 years in Asia and Latin America.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


    June 2016

  154. Demonstration of the Blood-Stage Plasmodium falciparum Controlled Human Malaria Infection Model to Assess Efficacy of the P. falciparum Apical Membrane Antigen 1 Vaccine, FMP2.1/AS01.
    J Infect Dis. 2016.
    PubMed     Text format    


  155. ATMAR RL, Baehner F, Cramer JP, Song E, et al
    Rapid Responses to Two Virus-Like Particle Norovirus Vaccine Candidate Formulations in Healthy Adults: A Randomized Controlled Trial.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  156. JEGASKANDA S, Luke C, Hickman HD, Sangster MY, et al
    The generation and protective ability of influenza-specific antibody-dependent cellular cytotoxicity in humans elicited by vaccination, natural infection or experimental challenge.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  157. MATTHIJSSE SM, Hontelez JA, Naber SK, Rozemeijer K, et al
    Public health benefits of routine human papillomavirus vaccination for adults in the Netherlands: a mathematical modeling study.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  158. RAMPLING T, Ewer KJ, Bowyer G, Bliss CM, et al
    Safety and High Level Efficacy of the Combination Malaria Vaccine Regimen of RTS,S/AS01B with ChAd-MVA Vectored Vaccines Expressing ME-TRAP.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  159. BOWEN MD, Mijatovic-Rustempasic S, Esona MD, Teel EN, et al
    Rotavirus Strain Trends during the Post-Licensure Vaccine Era: United States, 2008-2013.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  160. REGULES JA, Cicatelli SB, Bennett JW, Paolino KM, et al
    Fractional third and fourth dose of RTS,S/AS01 malaria candidate vaccine: a phase 2a controlled human malaria infection and immunogenicity study.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  161. MEITES E, Gorbach PM, Gratzer B, Panicker G, et al
    Monitoring for HPV Vaccine Impact among Gay, Bisexual and other Men who have Sex with Men - United States, 2012-2014.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  162. TOTA JE, Ramanakumar AV, Villa LL, Richardson H, et al
    Cervical Infection with Vaccine Human Papillomavirus (HPV) Genotypes as a Predictor of Acquisition and Clearance of Other HPV Infections.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


    May 2016
  163. MOHN KG, Brokstad KA, Pathirana RD, Bredholt G, et al
    Live attenuated influenza vaccination in children induces B-cell responses in tonsils.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  164. SCRIBA TJ, Kaufmann SH, Lambert PH, Sanicas M, et al
    Vaccination against tuberculosis with whole cell mycobacterial vaccines.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  165. DE ST MAURICE A, Schaffner W, Griffin MR, Halasa N, et al
    Persistent gender disparities in invasive pneumococcal diseases in the conjugate vaccine era.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  166. LAPRISE JF, Markowitz LE, Chesson HW, Drolet M, et al
    COMPARING 2- AND 3-DOSE 9-VALENT HPV VACCINE SCHEDULES IN THE U.S.: A COST-EFFECTIVENESS ANALYSIS.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  167. PRELOG M, Gorth P, Zwazl I, Kleines M, et al
    Universal mass vaccination against Rotavirus: indirect effects on Rotavirus infections in neonates and non-vaccinated small infants not eligible for vaccination.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  168. FLANNERY B, Zimmerman RK, Gubareva LV, Garten RJ, et al
    Enhanced genetic characterization of influenza A(H3N2) viruses and vaccine effectiveness by genetic group, 2014-2015.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  169. ALI D, Banda R, Mohammed A, Adagadzu J, et al
    Strengthening Routine Immunization in Areas of Northern Nigeria at High Risk for Polio Transmission During 2012-2014.
    J Infect Dis. 2016;213 Suppl 3:S147-50.
    PubMed     Text format     Abstract available


  170. GALI E, Mkanda P, Banda R, Korir C, et al
    Revised Household-Based Microplanning in Polio Supplemental Immunization Activities in Kano State, Nigeria. 2013-2014.
    J Infect Dis. 2016;213 Suppl 3:S73-8.
    PubMed     Text format     Abstract available


  171. JOHNSON MULUH T, Hamisu AW, Craig K, Mkanda P, et al
    Contribution of Environmental Surveillance Toward Interruption of Poliovirus Transmission in Nigeria, 2012-2015.
    J Infect Dis. 2016;213 Suppl 3:S131-5.
    PubMed     Text format     Abstract available


  172. CRAIG KT, Verma H, Iliyasu Z, Mkanda P, et al
    Role of Serial Polio Seroprevalence Studies in Guiding Implementation of the Polio Eradication Initiative in Kano, Nigeria: 2011-2014.
    J Infect Dis. 2016;213 Suppl 3:S124-30.
    PubMed     Text format     Abstract available


  173. MUSA A, Mkanda P, Manneh F, Korir C, et al
    Youth Group Engagement in Noncompliant Communities During Supplemental Immunization Activities in Kaduna, Nigeria, in 2014.
    J Infect Dis. 2016;213 Suppl 3:S91-5.
    PubMed     Text format     Abstract available


    April 2016
  174. PRADOS-ROSALES R, Carreno LJ, Weinrick B, Batista-Gonzalez A, et al
    The Type of Growth Medium Affects the Presence of a Mycobacterial Capsule and Is Associated With Differences in Protective Efficacy of BCG Vaccination Against Mycobacterium tuberculosis.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


    March 2016
  175. MINHINNICK A, Harris S, Wilkie M, Peter J, et al
    Optimization of a Human Bacille Calmette-Guerin Challenge Model: A Tool to Evaluate Antimycobacterial Immunity.
    J Infect Dis. 2016;213:824-30.
    PubMed     Text format     Abstract available


    October 2015
  176. JONES T
    Comment on Ly and Klevens, Trends in Disease and Complications of Hepatitis A Virus Infection.
    J Infect Dis. 2015.
    PubMed     Text format    


    September 2015
  177. CLIFF JM, Cho JE, Lee JS, Ronacher K, et al
    Excessive Cytolytic Responses Predict Tuberculosis Relapse After Apparently Successful Treatment.
    J Infect Dis. 2015.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Vaccines is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: